JP2010526101A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526101A5
JP2010526101A5 JP2010506688A JP2010506688A JP2010526101A5 JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5 JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5
Authority
JP
Japan
Prior art keywords
use according
compound
composition
unit dose
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062518 external-priority patent/WO2008137753A2/en
Publication of JP2010526101A publication Critical patent/JP2010526101A/ja
Publication of JP2010526101A5 publication Critical patent/JP2010526101A5/ja
Withdrawn legal-status Critical Current

Links

JP2010506688A 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与 Withdrawn JP2010526101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (2)

Publication Number Publication Date
JP2010526101A JP2010526101A (ja) 2010-07-29
JP2010526101A5 true JP2010526101A5 (enExample) 2011-06-23

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506688A Withdrawn JP2010526101A (ja) 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311795B2 (en) * 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
MX2009009492A (es) * 2007-03-06 2009-09-15 Novartis Ag Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
KR20100020455A (ko) * 2007-05-02 2010-02-22 포톨라 파마슈티컬스, 인코포레이티드 상이한 결정질 형태의 [4-(6-플루오로-7-메틸아미노-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐]-5-클로로-티오펜-2-일-술포닐우레아염, 및 이의 제약 조성물
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
SI2498731T1 (sl) 2009-11-11 2020-05-29 Chiesi Farmaceutici S.P.A. Postopki zdravljenja ali preprečevanja tromboze stenta
EP2515871B1 (en) * 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
UA125531C2 (uk) 2017-03-15 2022-04-13 Ідорсія Фармасьютікалз Лтд ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2006311795B2 (en) 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Similar Documents

Publication Publication Date Title
JP2010526101A5 (enExample)
US12220392B2 (en) Combination composition
JP2020033360A5 (enExample)
JP2008535867A5 (enExample)
JP2011173928A5 (enExample)
JP2009102342A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
TWI894333B (zh) 血管收縮素ii受體拮抗劑代謝產物與nep抑制劑的複合物用於心臟衰竭的應用
ES2671926T3 (es) Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
ES2508490T3 (es) Formulación de trimetazidina con diferentes perfiles de liberación
JP2020510043A5 (enExample)
CA2964684A1 (en) Composition for the treatment of conditions involving muscular pain
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
CN102247330B (zh) 一种以红花黄色素为原料制备的缓释片剂及其制备方法
TWI631944B (zh) 氯硝柳胺及其衍生物的用途
KR20120089444A (ko) 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
Myers et al. Infection and pheochromocytoma
JP2008527034A5 (enExample)
CN103933034B (zh) 一种含有木犀草素的药物组合物及应用
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
RU2004108117A (ru) Нептидиларгинали и способы лечения синдрома диссеминированного внутрисосудистого свертывания
WO2007000967A1 (ja) 脳梗塞治療薬
CN103127008A (zh) 长春西汀口服制剂的改进配方及用途